ABVD, Stanford V Regimens Equally Effective in Stage I, II Hodgkin's

Results of a new study show no significant difference between the standard of care in Hodgkin's lymphoma, ABVD plus radiotherapy, and the Stanford V regimen, in patients diagnosed with either stage I or stage II locally extensive, bulky mediastinal disease.

Researchers published their findings online in the Journal of Clinical Oncology.

This was a planned subgroup analysis from the phase III North American Intergroup E2496 Trial (Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma).

A total of 794 patients were included in the initial study, and 264 qualified for the subgroup analysis, having had stage 1 or 2 locally extensive, bulky mediastinal disease.

Out of them, 135 patients received six to eight cycles of ABVD every 28 days, while 129 received Stanford V once weekly for 12 weeks.

All patients then were given 36 Gy of modified involved field radiotherapy to the mediastinum, hila, and supraclavicular regions 2 to 3 weeks after finishing chemotherapy.

Results showed that the overall response rate was 83% in the ABVD group compared with 88% in the Stanford V group (P=0.40) and the complete response rates were 75% and 81% in the ABVD and Stanford V groups (P=0.30), respectively.

“This is the first prospective trial reporting outcomes specific to this subgroup, and it sets a benchmark for comparison of ongoing and future studies,” the research team wrote.

Source: JCO

lymphoma roundup

More Articles

More Articles

In T cell lymphoma, T lymphocytes, which are an essential part of the body's immune response, become malignant. T cell lymphomas account for about...

Lymphomatoid Papulosis (LyP) is a rare skin disorder that involves cancerous looking skin lesions. It is more than a skin condition; it is the...

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is a relatively rare B-cell subtype of non-Hodgkin'...

T-Cell Lymphoblastic Lymphoma (T-LBL) is a very rare subtype of non-Hodgkin's lymphoma. It tends to develop in...

In general, a diagnosis of T-cell lymphoma denotes a poorer prognosis than a diagnosis of B-cell lymphoma. One of...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...